PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of cevrwww.ecevr.orgAims and ScopeClinical and Experimental Vaccine ResearchInformation for Contributorse-SubmissionThis Article
 
Clin Exp Vaccine Res. 2013 July; 2(2): 74–75.
Published online 2013 July 3. doi:  10.7774/cevr.2013.2.2.74
PMCID: PMC3710926

Clinical and Experimental Vaccine Research is now registered in PubMed Central, PubMed, KoreaMed, and KoreaMed Synapse

Jung Soo Kim, President, Korean Vaccine Society1 and Chong-Woo Bae, Editor-in-chief, Clin Exp Vaccine Rescorresponding author2

The official journal of The Korean Vaccine Society, Clinical and Experimental Vaccine Research (Clin Exp Vaccine Res) is now registered in PubMed Central and PubMed by the date of April 19, 2013, and KoreaMed, and KoreaMed Synapse by date of July 30, 2013.

The registry on to the most prestigious databases within 1 year after launching is a very impressive achievement. We believe that the publication standard, e-journal supplementation process in the homepage and quality of the articles have been acknowledged at high international standards. We express deep gratitude to all those who helped with the foundation and processing of Clin Exp Vaccine Res and especially for those who submitted high standard manuscripts to Clin Exp Vaccine Res. The registry in PubMed Central and PubMed gives us the great opportunity to inform internationally both Clin Exp Vaccine Res and The Korean Vaccine Society.

Since April 19, 2013, all abstracts are available for search on PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) and the full version of all articles are available through link to the Clin Exp Vaccine Res web-site (http://www.ecevr.org). All articles are also available at PubMed Central (http://www.ncbi.nlm.nih.gov/pmc/) and the Clin Exp Vaccine Res web-site is available for access at this site. Moreover, through the CrossRef system, all Clin Exp Vaccine Res articles in citation in another journal are directly linked and available at the Clin Exp Vaccine Res web-site. Through these processes, we hope that Clin Exp Vaccine Res expands and develops into an internationally acknowledged and highly accredited journal.

During the past year after publication of the first edition, Clin Exp Vaccine Res has been registered many databases including NLM catalog, CAS, ICMJE, EBSCO, and DOAJ, etc. Registry in PubMed Central, and PubMed is a great achievement and reflects the robust development Clin Exp Vaccine Res has gone through within such a short time.

Clin Exp Vaccine Res has been accepted in March, 2013 for membership in the Korean Association of Medical Journal Editors and now registered in KoreaMed, and KoreaMed Synapse. Through this, Clin Exp Vaccine Res will also be enrolled in the important domestic databases and this will lead to further connections to international databases. Also, 2 years after publication of the first edition, application for SCOPUS and EMBASE is feasible and we are working in strengthening all needs for Clin Exp Vaccine Res, including inviting prestigious reviewers from throughout the world.

The next goal is qualification for SCI and SCIE. This will take time. For this, the following two strategies are essential, many high quality articles must be published in Clin Exp Vaccine Res and the impact factor of Clin Exp Vaccine Res must be high. This will take at least more than 2-3 years. Therefore, for the following 2-3 years, we ask for your support for submission of many high quality articles (especially by authors from other countries) and citation of articles in Clin Exp Vaccine Res in other articles published in SCI(E) journals.

A high standard journal is a reflection of the quality and standards of an academic society. The registry of Clin Exp Vaccine Res into PubMed Central and PubMed is an important opportunity for expanding acknowledgement of Clin Exp Vaccine Res and The Korean Vaccine Society.

We kindly ask for your warm hearted interest in the growth and development of Clin Exp Vaccine Res. The members of Clin Exp Vaccine Res will endeavor to make up to your expectations.

We thank those who worked so hard and supported us through the many processes in publication and establishment of the web-site, especially Jung Soo Kim, the President of The Korean Vaccine Society and other committee members, the authors of the articles published in Clin Exp Vaccine Res, the Editors and Reviewers of Clin Exp Vaccine Res, Director Yong-Hoon Joo and faculty members at Academya Co., Director Hye-Suk Chang and all members at XMLink Co., Director Hye Min Cho and faculty at Infolumi Co., Director In-Kwon Hwang of Inkwon & Partners Co., Oh-Hoon Kwon, Director of Committee on Information, Korean Association of Medical Journal Editors, Prof. Choon Shil Lee, Department of Library and Information Science, Sookmyung Women's University and all who participated in the launching and publication of Clin Exp Vaccine Res. Thank you so much for your generous interest and support which made this all possible.

Footnotes

No potential conflict of interest relevant to this article was reported.


Articles from Clinical and Experimental Vaccine Research are provided here courtesy of Korean Vaccine Society